Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase (ESBL)-Producing Pathogens: a Randomized Double-blind Non-inferiority Trial.

NCT06342115 is registered in ClinicalTrials.gov with Beneficência Portuguesa de São Paulo as lead sponsor.

NCT NCT06342115
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06342115 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase (ESBL)-Producing Pathogens: a Randomized Double-blind Non-inferiority Trial.
Lead sponsor
Beneficência Portuguesa de São Paulo
Phase
Phase 4
Overall status
Recruiting
Start date
March 26, 2025
Completion date
December 31, 2027
Enrollment
55 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

febrile neutropenia